Real-World Innovation Pioneering chemical Discovery with Generative AI
Harnessing computational chemistry and generative AI to meet real-world commercial product needs in pharma and agriculture.
AI INNOVATION IN PHARMA AND AGRICULTURE MEANS A BETTER WORLD FOR ALL
Over 90% small-molecule failure rate in reaching commercial phase, demands
a disruptive approach
Evogene bridges the gap between commercial product needs of the pharmaceutical and ag-chemical industries and specifically tailored computational innovation. Our unique approach has the potential to translate generative AI discoveries into practical, commercially viable products.
ChemPass AI™: A Proprietary AI-First TECH-ENGINE for Optimized Multi-Parameter Novel Small Molecule Design
At the core of Evogene is ChemPass AI™, a proprietary generative AI tech-engine – creating highly potent, unique small molecules optimized across multiple critical parameters – increasing the probability of success while reducing time and costs.
BOAZ MAOZ
MANAGING DIRECTOR
GOOGLE CLOUD ISRAEL
“We’re pleased to collaborate with Evogene’s innovation in AI-powered molecule design. Their progress with ChemPass AI highlights the strength of pairing advanced AI infrastructure with deep scientific insight. We look forward to seeing the impact of this new model in drug discovery and agriculture.”
Real Collaboration
Joint Creation
By leveraging strategic partnerships or our own in-house expertise, with ChemPass AI’s capabilities for small molecule design, we facilitate the development of market-ready products for both drug discovery and agricultural chemicals. This flexible business approach enables us to explore a wider range of product development opportunities and maximize our impact in the real world.
Evogene subsidiary
VID HEGDE Former vp of crop protection discovery and development
“The collaboration with AgPlenus has accelerated the identification of a class of herbicide chemistry that targets a new mode-of-action for weed control, something the industry has been lacking for decades."
Evogene subsidiary
Rachel rama
Head of small molecules
crop science devision
“Bringing together AgPlenus’ expertise with Bayer’s CropKey approach to crop protection innovation will help accelerate the delivery of essential, sustainable, and affordable solutions to farmers and set a new benchmark in the industry.”
Pharma Division
Dr. Richard Novak CEO, Unravel Biosciences
“We are thrilled to partner with Evogene to design an optimized new therapeutic candidates to promote remyelination for MS and other neurodegenerative disorders. The synergistic combination of Evogene’s Chempass-AI platform and generative chemistry together with Unravel’s patient RNA-derived Living Molecular Twins™ demonstrates the acceleration of drug development driven by novel data and advanced algorithms since patients cannot wait.”
Pharma Division
professor ehud gazit a world leader in the field of Molecular self-assembly
“We are excited to join forces with Evogene in this groundbreaking endeavor. For more than a decade, our research has revealed for the first time how small metabolites can self-assemble into amyloid-like structures that contribute to the pathology of numerous rare and common diseases. By integrating our fundamental understanding of molecular self-assembly with Evogene’s cutting-edge AI-driven drug design platform, we have a unique opportunity to develop novel therapeutics that specifically target these pathological processes and ultimately improve treatment for patients.”
